NASDAQ : IPHA
Innate Pharma S.A. — Key statistics
Healthcare · Biotechnology · France
Last price 1.5 USD (Oct 30, 2026, 9:37 AM EDT) · Market cap 134.53M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 126.01M |
| Enterprise Value | 136.40M |
Dates
| Measure | Value |
|---|
| Earnings Date | Sep 17, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 93.70M |
| Shares Change (YoY) | +10.65% |
| Shares Change (QoQ) | +1.71% |
| Owned by Insiders (%) | 0.74% |
| Owned by Institutions (%) | 6.04% |
| Float | 68.87M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 20.22 |
| PS Ratio | 11.73 |
| Forward PS | 12.37 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 12.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.60 |
| Quick Ratio | 0.47 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -124.92 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -46.60% |
| Return on Invested Capital (ROIC) | -2,545.08% |
| Return on Capital Employed (ROCE) | -2,545.08% |
| Weighted Average Cost of Capital (WACC) | 9.40% |
| Revenue Per Employee | $93,378 |
| Profits Per Employee | -$451,807 |
| Employee Count | 120 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.19 |
| 52-Week Price Change | -28.93% |
| 50-Day Moving Average | 1.75 |
| 200-Day Moving Average | 1.71 |
| Relative Strength Index (RSI) | 36.10 |
| Average Volume (20 Days) | 22,746 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 126,864 |
| Short Previous Month | 88,622 |
| Short % of Shares Out | 0.11% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.09 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 11.21M |
| Gross Profit | -34.47M |
| Operating Income | -54.37M |
| Pretax Income | -54.22M |
| Net Income | -54.22M |
| EBITDA | -53.65M |
| EBIT | -54.37M |
| Loss Per Share | -$0.57 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 12.45M |
| Total Debt | 23.08M |
| Net Cash | -10.64M |
| Net Cash Per Share | -$0.11 |
| Equity (Book Value) | -46.28M |
| Book Value Per Share | -0.49 |
| Working Capital | -15.14M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -47.74M |
| Capital Expenditures | -192,590 |
| Depreciation & Amortization | 706,535 |
| Net Borrowing | -7.64M |
| Free Cash Flow | -47.93M |
| FCF Per Share | -$0.51 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -485.25% |
| Pretax Margin | -483.85% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -10.65% |
| Shareholder Yield | -10.65% |
| Earnings Yield | -40.80% |
| FCF Yield | -36.48% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $6.67 |
| Price Target Difference | 376.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 124.72% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -21.88 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |